Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Linda Hagerman"'
Autor:
John Hilton, Karen Gelmon, Philippe L. Bedard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek Jonker, Aaron R. Hansen, Zachary W. Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu Chen, Deb Kellar, Irene Li, Sung-Eun Lee, Takako Kono, Brian Y. C. Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria-Bretones, Eric Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparicio, David W. Cescon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.
Externí odkaz:
https://doaj.org/article/ee095627571b4e258e1890f77d3d7597
Autor:
Stephen K. Chia, Susan L. Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Rachel Goodwin, Tao Wang, Shingo Sakashita, Ming S. Tsao, Elizabeth Eisenhauer, Penelope Bradbury
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-8 (2017)
Abstract Background The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foret
Externí odkaz:
https://doaj.org/article/339a000fc2ce4f629f2c9ae8021f9690
Autor:
David W. Cescon, John Hilton, Philippe Bedard, Phillip Blanchette, Rossanna C. Pezo, Ayesha Bashir, Vikaash Kumar, Terry L. Ng, Arif Awan, Anthony Lott, Jacques Antoun Raphael, Linda Hagerman, Mark Bray, Lindsay Muyot, Jesus Fuentes Antras, Lesley Seymour, Dongsheng Tu, Pierre-Olivier Gaudreau, Moira Rushton
Publikováno v:
Cancer Research. 83:P3-07
Background: CFI-400945 is a selective oral inhibitor of Polo-like Kinase 4 (PLK4), a controller of centriole duplication and mitotic progression identified by functional screening of genomically unstable breast cancer (BC). IND.237 (NCT01954316) is a
Autor:
Philippe Bedard, Mihaela Mates, John Hilton, Nathalie Levasseur, Arif Awan, Amirrtha Srikanthan, David W. Cescon, Karen Gelmon, Andrew Robinson, Nancy Drummond-Ivars, Irene Li, Laleh Rastgou, Jackie Edwards, Linda Hagerman, Siwei Zhang, Mark Bray, Lesley Seymour, Moira Rushton, Pierre-Olivier Gaudreau
Publikováno v:
Cancer Research. 83:P3-07
CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC) Philippe L. Bedard, Mihaela Mates, John Hilton, Nathalie Levasseur, Arif Awan, Amirrtha Srikanthan, David
Autor:
John Hilton, David W. Cescon, Andrew Robinson, Sukhbinder Dhesy-Thind, Sara Taylor, Arif Awan, Terry L. Ng, Moira Rushton, Marie-France Savard, Lindsay Muyot, Marie Claude Reeves, Linda Hagerman, Hongbo Lui, Mark Bray, Dongsheng Tu, Lesley Seymour, Pierre-Olivier Gaudreau
Publikováno v:
Cancer Research. 83:P3-07
CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC) John Hilton, David W. Cescon, Andrew Robinson, Sukhbinder Dhesy-Thind, Sara Kristina Taylor, Arif Awan, Terry Ng, Moir
Autor:
Tanya Skamene, Wanda Hasegawa, Anca Prica, Lilian Amrein, Sarit Assouline, Raquel Aloyz, Stephen Caplan, Laura Rodriguez, Sue Robinson, Anthea Peters, Bingshu E. Chen, Carolyn Owen, Linda Hagerman, Annette E. Hay, Lawrence Panasci, Versha Banerji, Sudeep Shivakumar
Publikováno v:
Leukemialymphoma. 61(7)
Buparlisib is an orally available pan-Class I PI3K inhibitor, that is more potent than idelalisib in vitro. Its distinct toxicities include hyperglycemia, hypertension, and mood disturbance. IND216...
Autor:
Christine E. Simmons, Mark Clemons, Lawrence Panasci, Karen A. Gelmon, Susan Dent, Lesley Seymour, Sukhbinder Dhesy-Thind, Shailendra Verma, H. Lui, Linda Hagerman, Kim N. Chi, Dongsheng Tu, Xinni Song, D. Ksienski, Mihaela Mates, Susan Ellard, Muhammad Salim, Harriet Feilotter, Vanessa Bernstein
Publikováno v:
Breast Cancer Research and Treatment. 167:485-493
Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents. This multicentre, randomized, phase II trial was undertaken to evaluate
Autor:
M. Mates, Penelope A. Bradbury, Caroline Lohrisch, Rachel Anne Goodwin, Ming-Sound Tsao, Stephen Chia, Shingo Sakashita, Tao Wang, Karen A. Gelmon, Susan Ellard, Catalin Mihalcioiu, Sara Kristina Taylor, Stephen Welch, Vikaash Kumar, Elizabeth A. Eisenhauer, Wilson H. Miller, Linda Hagerman
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-8 (2017)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foretinib is a
Autor:
John Hilton, Jean M. Seely, Paul Wheatley-Price, John R. Goffin, Linda Hagerman, Ronald Feld, Christopher W. Lee, Nevin Murray, Andrew Maksymiuk, Quincy Chu, Penelope A. Bradbury, Ashish Gupta, Glenwood D. Goss, Maria Bonomi
Publikováno v:
Journal of Thoracic Oncology. 11:2018-2021
There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting angiogenesis is an area of investigation. PF-03446962 is a fully human antibody against activin receptor-like kinase 1, which is commonly
Autor:
S. Zhang, Arif Awan, M. Rushton, Andrew Robinson, P-O. Gaudreau, Linda Hagerman, I. Li, M. Mates, L. Rastgou, Caroline A. Lohrisch, J. Edwards, P. Bedard, N. Drummond-Ivars, Karen A. Gelmon, Xinni Song, John Hilton, Dongsheng Tu, M. Bray, Amirrtha Srikanthan
Publikováno v:
Annals of Oncology. 32:S16